

**FORM 9**  
**NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**  
**(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Name of Listed Issuer:	Symbol(s):
Britannia Life Sciences Inc. (the "Issuer").	BLAB

Date: January 5, 2022

Is this an updating or amending Notice: No.

If yes provide date(s) of prior Notices: Not applicable.

Issued and Outstanding Securities of Issuer Prior to Issuance: 158,884,339

**Pricing:**

Date of news release announcing proposed issuance: January 5, 2022. or

Date of confidential request for price protection: Not applicable.

Closing Market Price on Day Preceding the news release: 0.18 or

Day preceding request for price protection: Not applicable.

**Closing:**

Number of securities to be issued: 3,000,000

Issued and outstanding securities following issuance: 161,884,339

**Instructions:**

1. For private placements (including debt settlement), complete Table 1A and Table 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons.
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to [listings@thecse.com](mailto:listings@thecse.com) with an appendix that includes the information in Table 1B for ALL places.

## Part 1. Private Placement

**Table 1A – Summary**

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
United Kingdom	1	\$0.18	\$540,000.00
<b>Total number of purchasers:</b>	1		
<b>Total dollar value of distribution in all jurisdictions:</b>			\$540,000.00

**Table 1B – Related Persons**

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date <sup>(1)</sup>	Describe relationship to Issuer <sup>(2)</sup>
Mark Bowes-Cavanagh, Devon, United Kingdom	3,000,000	\$0.18	-	Distribution outside of Canada	15,600,000	2022-01-05	Insider

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$540,000
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

Britannia Bud Holdings Inc. ("**Britannia Bud**") and Mark Richard Bowes-Cavanagh, Claire Suzanne Bowes-Cavanagh, Jonathan Bird Sumner and Robert Sumner (each a "Seller", collectively the "Sellers") entered into a share purchase agreement dated March 10, 2020, wherein Britannia Bud acquired 60% of the issued share capital of Advanced Development and Safety Laboratories (United Kingdom) ("ADSL"), which includes optionality to purchase the remaining 40% interest in ADSL (the "**ADSL Purchase Agreement**") from the Sellers who have retained ownership of the 40% interest. Completion payments in relation to this agreement were made on February 9, 2021. Due to challenging capital market dynamics and delays associated with the COVID-19 pandemic, the Sellers agreed to defer a portion of the purchase price and entered into a sellers' note agreement on February 9, 2021, as amended on June 15, 2021 (the "**Sellers' Note Agreement**") pursuant to which the Sellers agreed to loan the sum of £4,456,812.58 to Britannia Bud, at an initial interest rate of 6% per annum, which increased to 10% from June 1, 2021, in connection with the amendment on June 15, 2021. The loan is due on December 31, 2021.

On June 4, 2021, the Sellers agreed to accept an extension of the term of the Sellers' Note Agreement in accordance with the penalties stipulated in the original agreement. Britannia agreed to pay a penalty fee of £200,000, as well as increasing the interest rate to 10% on the outstanding balance. On February 9, 2021, Britannia additionally agreed to purchase an additional 10% of the ADSL, in accordance with a portion of the optionality rights established in the original ADSL

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

Purchase Agreement. The outside date on the completion of the exercise of the option and payment of the purchase price is 180 days following the completion of the reverse takeover of RISE Life Science Corp. by Britannia Bud, being May 11, 2022.

On December 23, 2021, the Issuer repaid £1,551,032.57 in principal amount owing under the Sellers' Note to the Sellers.

On January 5, 2022, the Sellers agreed to extend the due date of the Sellers' Note Agreement from December 31, 2021 to February 28, 2022. A fee of \$540,000 has been paid to Mark Bowes-Cavanagh for his services in connection with securing such extension from the Sellers. The Issuer is settling the payment of this fee through the issuance of 3,000,000 common shares, at a price of \$0.18 per common share.

For more details on ADSL, the Seller's Note Agreement and the ADSL Purchase Agreement, please see the Issuer's listing statement dated October 29, 2021, which is available on SEDAR ([www.sedar.com](http://www.sedar.com)) under the Issuer's profile.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: Not applicable.
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.

On January 5, 2021, the Sellers agreed to extend the due date of the Sellers' Note Agreement from December 31, 2021 to February 28, 2022. A fee of \$540,000 has been paid to Mark Bowes-Cavanagh for his services in connection with securing such extension from the Sellers. The Issuer is settling the payment of this fee through the issuance of 3,000,000 common shares, at a price of \$0.18 per common share.

5. Description of securities to be issued:

**Common Shares**

- (a) Class Common Shares.
  - (b) Number 3,000,000.
  - (c) Price per security \$0.18
  - (d) Voting rights 1 vote per common share.
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
    - (a) Number Not applicable.
    - (b) Number of securities eligible to be purchased on exercise of warrants (or options) Not applicable.
    - (c) Exercise price Not applicable.

- (d) Expiry date Not applicable.
7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount Not applicable.
- (b) Maturity date Not applicable.
- (c) Interest rate Not applicable.
- (d) Conversion terms Not applicable.
- (e) Default provisions Not applicable.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): Not applicable.
- (b) Cash Not applicable.
- (c) Securities Not applicable.
- (d) Other Not applicable.
- (e) Expiry date of any options, warrants etc. Not applicable.
- (f) Exercise price of any options, warrants etc. Not applicable.
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship. Not applicable.
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).  
Not applicable.
11. State whether the private placement will result in a change of control.  
The issuance contemplated herein will not result in a change of control.
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. Not applicable.
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate

legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

**Part 2. Acquisition – Not Applicable.**

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: \_\_\_\_\_  
\_\_\_\_\_.
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: \_\_\_\_\_  
\_\_\_\_\_.
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
  - (a) Total aggregate consideration in Canadian dollars: \_\_\_\_\_.
  - (b) Cash: \_\_\_\_\_.
  - (c) Securities (including options, warrants etc.) and dollar value: \_\_\_\_\_  
\_\_\_\_\_.
  - (d) Other: \_\_\_\_\_.
  - (e) Expiry date of options, warrants, etc. if any: \_\_\_\_\_.
  - (f) Exercise price of options, warrants, etc. if any: \_\_\_\_\_.
  - (g) Work commitments: \_\_\_\_\_.
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc.).
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: \_\_\_\_\_  
\_\_\_\_\_.
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer(1)

**Notes:**

- (1) Indicate if Related Person
7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: \_\_\_\_\_  
\_\_\_\_\_.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): \_\_\_\_\_  
\_\_\_\_\_.
- (b) Cash \_\_\_\_\_.
- (c) Securities \_\_\_\_\_.
- (d) Other \_\_\_\_\_.
- (e) Expiry date of any options, warrants etc. \_\_\_\_\_.
- (f) Exercise price of any options, warrants etc. \_\_\_\_\_.
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_.
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. \_\_\_\_\_  
\_\_\_\_\_.

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF  
LISTED SECURITIES**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The Issuer has obtained the express written consent of each applicable individual to:
  - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
  - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time.
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated January 5, 2022.

Peter Shippen  
Name of Director or Senior Officer

(signed) Peter Shippen  
Signature

Director and Chief Executive Officer  
Official Capacity

**APPENDIX A**  
**PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9**

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, "CSE or the "Exchange") collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange's obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9<sup>th</sup> Floor, Toronto, ON, M5J 2W4.